Naloxone Direct Program 2025-2026

The Division of Care and Treatment Services is seeking applications for the 2025-2026 Naloxone Direct Program.

The Naloxone Direct Program provides naloxone, an opioid overdose reversal medication, at no cost to eligible agencies for free distribution to people at risk for an opioid-related overdose and to people who may witness an opioid-related overdose.

• To better align with best practice principles and evidence-based practices, the products available include: 3 mg nasal naloxone, 4 mg nasal naloxone, and 0.4 mg/1 ml intramuscular naloxone. One, two, or all three formulations can be requested.
• EMS agencies operating leave behind programs are eligible to submit an application. Leave behind programs distribute naloxone to people who survived an opioid-related overdose, to people at risk for an opioid-related overdose, and/or the social networks of the focus populations (friends, family, roommates, etc.). This change is designed to support sustainability of EMS agency leave behind programs.
• Opioid treatment programs are no longer eligible to submit an application. Opioid treatment programs were included in this program during the COVID-19 public health emergency. The COVID-19 public health emergency and related temporary funding have ended.

While there is no limit to the amount of naloxone an agency can request through this application process, awards will be made based on the reasonableness of the request and availability of funds. Applicants should base their request on prior experience, community need, and their plan to achieve naloxone saturation.

Awarded agencies will be notified by the Division of Care and Treatment Services. This notification will provide information on the amount of naloxone awarded to the agency for the 2025-2026 program period. It will also provide instructions on how to order naloxone through this program. Naloxone ordered through this program will be shipped directly from the manufacturer to awarded agencies for distribution. A team of technical advisors from the Division of Care and Treatment Services will provide program support and can assist with overcoming barriers, facilitating partnerships, and providing tailored assistance to achieve community naloxone saturation.

DHS supports compassionate overdose response. An important piece of this evidence-based and person-centered approach is to respect and support a person's right to make decisions about their own life. Making space for this autonomy is essential for the success of any overdose prevention program. This is why more formulations of naloxone now are available through the Naloxone Direct Program.

3 mg nasal naloxone (RiVive ^TM ) - Order by the case

• Two doses per kit
• 24 doses per case
• Kit dimensions: 1.063” L x 6.125” W x 3.625” H

4 mg nasal naloxone (NARCAN ^® ) - Order by the case

• Two doses per kit
• 12 doses per case
• Kit dimensions: 9.28” L x 2.39” W x 5.61” H

0.4 mg/1 ml intramuscular naloxone - Order by the case

• Two doses per kit with two IM syringes
• 12 doses and 12 IM syringes per case
• Kit dimensions: 7” W x 6” H x 0.25” D

Long-acting/high-dose overdose reversal medications are not offered through this program. See the DHS statement on long-acting/high-dose reversal medication .

• Wisconsin county human services departments (or their designee)
• Tribal health clinics in Wisconsin (or their designee)
• Local health departments in Wisconsin (or their designee)
• Community recovery organizations located in and serving people in Wisconsin (independent, nonprofit organizations led and governed by individuals in recovery and their family members) Agencies may need to submit verification of their status as a community recovery organization.
• Syringe services programs located in and serving people in Wisconsin
• Agencies providing emergency medical services located in and serving people in Wisconsin as an emergency medical responder service provider, non-transporting EMS provider, or ambulance service provider as defined by Wis. Admin. Code § DHS 110.04(25)

Complete this online form to apply for the 2025-2026 Naloxone Direct Program . Applications are due October 27, 2025.

View all questions in this application (PDF) . Some questions are not displayed in the application. Questions appear based on answers to previous questions.

It may take up to 15 minutes to complete this application. Select the "Save and Continue Later" option at the top of the screen to save your work and get instructions on how to come back later to complete the application.

Send questions about the Naloxone Direct Program to DHSDCTSNaloxoneDirect@dhs.wisconsin.gov .